This radiotherapy combined with chemotherapy improves the survival rate of colorectal cancer

Share This Post

New research shows that in patients with liver or liver-dominant metastatic colorectal cancer , the addition of selective internal radiation therapy to standard first-line mFOLFOX6 chemotherapy results in a significant increase in the survival of patients with primary tumors on the right.

SIRT, which has been used in Europe since 2003, is an internal radiotherapy using Y-90 resin microspheres (diameters between 20 and 60 microns) delivered in the hepatic artery using a catheter Beta radiation emitting microspheres are preferentially placed in the microvessels around the tumor, minimizing systemic effects.

The SIRFLOX, FOXFIRE and FOXFIRE global studies aimed to evaluate the efficacy and safety of SIRT plus first-line oxaliplatin chemotherapy for unresectable mCRC.

For 554 patients who received chemotherapy plus SIRT and 549 patients who received chemotherapy only, the results showed that the median survival time of the left tumor of mCRC patients in the chemotherapy plus SIRT group was 24.6 months, compared with 26.6 months in the chemotherapy alone group, but SIRT chemotherapy The median survival of mCRC patients with unilateral tumors was 22 months in the group and 17.1 months in the chemotherapy alone group, which was 5 months longer.

At a news conference, Dr. Harpreet Wasan told Imperial College Health Care NHS Trust in the UK that a hypothesis is that the right side cancer not only […] worsens but is more resistant to chemotherapy. They may be more sensitive to radiation therapy, which has a completely different mechanism of action.

Dr. Wasan added that the lack of positive findings in the overall analysis may be due to the inclusion of patients with metastatic cancer outside the liver. He said: “Although SIRT can control liver diseases, it cannot control diseases outside the liver.”

https://www.medicalnewstoday.com/articles/318283.php

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Limkato Korea’s first CAR T Cell therapy
CAR T-Cell therapy

Limkato: Korea’s first CAR T Cell therapy

South Korea is making significant strides in **CAR T cell therapy**, highlighted by the approval of **Limkato**, the first domestically developed CAR T therapy by **Curocell** in 2023. This milestone reduces reliance on foreign treatments and boosts Korea’s position in the global biotech industry. With strong government support and cutting-edge research, Korea is poised to advance CAR T therapies further, expanding applications and improving accessibility for cancer patients.

TIL therapy for melanoma in China
Melanoma

TIL therapy for melanoma in China

Tumor-Infiltrating Lymphocyte (TIL) therapy represents a promising advancement in the treatment of melanoma, particularly in cases where traditional treatments have failed. In China, the adoption of TIL therapy is gaining momentum, offering new hope to patients battling this aggressive form of skin cancer.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

CancerFax is the most trusted online platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies.

Send your medical reports and get a free analysis.

🌟 Join us in the fight against cancer! 🌟

Привет,

CancerFax — это самая надежная онлайн-платформа, призванная предоставить людям, столкнувшимся с раком на поздних стадиях, доступ к революционным клеточным методам лечения.

Отправьте свои медицинские заключения и получите бесплатный анализ.

🌟 Присоединяйтесь к нам в борьбе с раком! 🌟